Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, Roussel M, Montes L, Cherel B, Chalopin T, Slama B, Chretien ML, Laribi K, Dingremont C, Roul C, Mariette C, Rigaudeau S, Calmettes C, Dib M, Tiab M, Vincent L, Delaunay J, Santagostino A, Macro M, Bourgeois E, Orsini-Piocelle F, Gay J, Bareau B, Bigot N, Vergez F, Lebreton P, Tabrizi R, Waultier-Rascalou A, Frenzel L, Le Calloch R, Chalayer E, Braun T, Lachenal F, Corm S, Kennel C, Belkhir R, Bladé JS, Joly B, Richez-Olivier V, Gardeney H, Demarquette H, Robu-Cretu D, Garderet L, Newinger-Porte M, Kasmi A, Royer B, Decaux O, Arnulf B, Belhadj K, Touzeau C, Mohty M, Manier S, Moreau P, Avet-Loiseau H, Corre J, Facon T. Leleu X, et al. Among authors: demarquette h. Nat Med. 2024 Aug;30(8):2235-2241. doi: 10.1038/s41591-024-03050-2. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830994 Free PMC article. Clinical Trial.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, Buisson L, Mahéo S, Do Souto Ferreira L, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Sanhes L, Orsini-Piocelle F, Fontan J, Chretien ML, Demarquette H, Mohty M, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: demarquette h. Blood. 2023 Mar 16;141(11):1308-1315. doi: 10.1182/blood.2022017863. Blood. 2023. PMID: 36375118 Free PMC article.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, Karlin L, Perrot A, Touzeau C, Chrétien ML, Rigaudeau S, Dib M, Nicolas-Virelizier E, Escoffre-Barbe M, Belhadj K, Mariette C, Stoppa AM, Araujo C, Doyen C, Fontan J, Kolb B, Garderet L, Brechignac S, Malfuson JV, Jaccard A, Lenain P, Borel C, Hebraud B, Benbrahim O, Dorvaux V, Manier S, Augeul-Meunier K, Vekemans MC, Randriamalala E, Chaoui D, Caers J, Chaleteix C, Benboubker L, Vincent L, Glaisner S, Zunic P, Slama B, Eveillard JR, Humbrecht-Kraut C, Morel V, Mineur P, Eisenmann JC, Demarquette H, Richez V, Vignon M, Caillot D, Facon T, Moreau P, Colin AL, Olivier P, Wuilleme S, Avet-Loiseau H, Corre J, Attal M. Roussel M, et al. Among authors: demarquette h. Blood. 2022 May 5;139(18):2747-2757. doi: 10.1182/blood.2021014635. Blood. 2022. PMID: 35511184 Free article. Clinical Trial.
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Cazaubiel T, Leleu X, Perrot A, Manier S, Buisson L, Maheo S, Do Souto Ferreira L, Lannes R, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Sanhes L, Orsini-Piocelle F, Fontan J, Chretien ML, Demarquette H, Mohty M, Schavgoulidze A, Avet-Loiseau H, Corre J. Cazaubiel T, et al. Among authors: demarquette h. Blood. 2022 Apr 28;139(17):2666-2672. doi: 10.1182/blood.2021014968. Blood. 2022. PMID: 35171994 Free article.
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S. Dimopoulos MA, et al. Among authors: demarquette h. Blood Cancer J. 2022 Jan 24;12(1):9. doi: 10.1038/s41408-021-00593-2. Blood Cancer J. 2022. PMID: 35075109 Free PMC article. Clinical Trial.
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods.
Corre J, Perrot A, Hulin C, Caillot D, Stoppa AM, Facon T, Leleu X, Dib M, Karlin L, Moreau P, Mohty M, Mariette C, Fontan J, Marolleau JP, Demarquette H, Slama B, Voillat L, Macro M, Orsini-Piocelle F, Brechignac S, Rey P, Collet P, Tiab M, Belhadj K, Lifermann F, Clement-Filliatre L, Sohn C, Richez V, Avet-Loiseau H; Intergroupe Francophone du Myélome (IFM). Corre J, et al. Among authors: demarquette h. Leukemia. 2021 Dec;35(12):3600-3603. doi: 10.1038/s41375-021-01250-0. Epub 2021 Jun 7. Leukemia. 2021. PMID: 34099876 No abstract available.
Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma.
Demonchy J, Cordier C, Fréalle E, Demarquette H, Herbaux C, Escure G, Willaume A, Van De Wyngaert Z, Noel MP, Facon T, Faure K, Caro J, Morgan G, Davies FE, Alfandari S, Bories C, Boyle EM. Demonchy J, et al. Among authors: demarquette h. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e545-e547. doi: 10.1016/j.clml.2021.01.019. Epub 2021 Feb 2. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33642203 No abstract available.
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.
Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, Belhadj K, Facon T, Hulin C, Mohty M, Fontan J, Macro M, Brechignac S, Jaccard A, Stoppa AM, Orsini-Piocelle F, Adiko D, Voillat L, Keddar F, Barry M, Demarquette H, Certain MN, Plantier I, Roussel M, Hébraud B, Filleron T, Attal M, Avet-Loiseau H. Corre J, et al. Among authors: demarquette h. Haematologica. 2020 Sep 1;105(9):e480-483. doi: 10.3324/haematol.2019.236588. Haematologica. 2020. PMID: 33054068 Free PMC article. No abstract available.
Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population.
Van de Wyngaert Z, Carpentier B, Pascal L, Lionne-Huyghe P, Leduc I, Srour M, Vasseur M, Demarquette H, Terriou L, Herbaux C, Manier S, Bossard JB, Barbieux S, Chauvet P, Willaume A, Nudel M, Bories C, Gibier JB, Facon T, Boyle EM. Van de Wyngaert Z, et al. Among authors: demarquette h. Br J Haematol. 2020 Feb;188(3):e24-e27. doi: 10.1111/bjh.16282. Epub 2019 Nov 19. Br J Haematol. 2020. PMID: 31742668 Free article. Clinical Trial. No abstract available.
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.
Boyle EM, Leleu X, Petillon MO, Karlin L, Doyen C, Demarquette H, Royer B, Macro M, Moreau P, Fostier K, Marie-Lorraine C, Zarnitsky C, Perrot A, Herbaux C, Poulain S, Manier S, Beauvais D, Walker BA, Wardell CP, Vincent L, Frenzel L, Caillon H, Susanna S, Dejoie T, Avet-Loiseau H, Mohty M, Facon T; IFM2014-04 investigators. Boyle EM, et al. Among authors: demarquette h. Br J Haematol. 2019 Nov;187(3):319-327. doi: 10.1111/bjh.16059. Epub 2019 Jun 19. Br J Haematol. 2019. PMID: 31218679 Free article. Clinical Trial.
27 results